Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LC-REVITALIZE: Repurposed Drugs for Long Covid
NCT06928272Phase 3Recruiting
- Start
- Sep 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial of pirfenidone and upadacitinib in post-COVID-19 condition (PCC) (4 arms). Primary endpoint: Symptom Burden Questionnaire Subscales at 6 months. Started Sep 2025; status: recruiting.
02
Drugs
pirfenidoneupadacitinib
03
Conditions
post-COVID-19 condition (PCC)
Beyond the preview
Go deeper on NCT06928272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06928272.